This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherpy treatment for lung cancer and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy for lung cancer and how to identify and manage common side effects of immunotherapy agents.
This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Clinical Director, SKCC at Sibley
Ticiana Leal, MD
UW Carbone Cancer Center
After completing this activity, the participant should be able to:
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: January 28, 2019 - January 28, 2020
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.
(Universal Activity Number - JA4008162-9999-19-603-H01-P)
Type of Activity: Knowledge
The maximum number of hours awarded for this Continuing Nursing Education activity is .8 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.
Ticiana Leal, MD - Consulting Fees: AbbVie, AstraZeneca, BMS, Novartis, Takeda
Tara Withington, CAE, Executive Director of SITC has an ownership interest as a partner at Executive Director, Inc.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.
Accreditation Council for Pharmacy Education
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.80
Including 0.4 pharmacotherapy contact hours
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s): 0.75
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s): 0.75
2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy)
This activity is presented free of charge.